European Journal of Internal Medicine
Volume 19, Issue 5 , Pages 340-344 , July 2008

Digital photography as an operational tool for assessing corticosteroid-induced lipodystrophy

  • Laurence Fardet

      Affiliations

    • Department of Internal Medicine, Hopital Saint-Antoine, 184 rue du Fbg Saint-Antoine, 75012 Paris, France
    • Department of Public Health, Hopital Tenon, INSERM UMR-S707, University Pierre et Marie Curie, 4 rue de la Chine, 75020 Paris, France
    • Corresponding Author InformationCorresponding author. Department of Internal Medicine, Hopital Saint-Antoine, 184 rue du faubourg Saint-Antoine, 75012 Paris, France. Tel.: +33 01 49 28 23 73; fax: +33 01 49 28 26 52.
    • ,
  • Adrien Kettaneh

      Affiliations

    • Department of Internal Medicine, Hopital Saint-Antoine, 184 rue du Fbg Saint-Antoine, 75012 Paris, France
    • ,
  • Kiet-Phong Tiev

      Affiliations

    • Department of Internal Medicine, Hopital Saint-Antoine, 184 rue du Fbg Saint-Antoine, 75012 Paris, France
    • ,
  • Bénédicte Fabre

      Affiliations

    • Department of Internal Medicine, Hopital Saint-Antoine, 184 rue du Fbg Saint-Antoine, 75012 Paris, France
    • ,
  • Cécile Tolédano

      Affiliations

    • Department of Internal Medicine, Hopital Saint-Antoine, 184 rue du Fbg Saint-Antoine, 75012 Paris, France
    • ,
  • Jean Cabane

      Affiliations

    • Department of Internal Medicine, Hopital Saint-Antoine, 184 rue du Fbg Saint-Antoine, 75012 Paris, France
    • ,
  • Antoine Flahault

      Affiliations

    • Department of Public Health, Hopital Tenon, INSERM UMR-S707, University Pierre et Marie Curie, 4 rue de la Chine, 75020 Paris, France

Received 27 March 2007 ,Accepted 26 September 2007.

References 

  1. Walsh LJ, Wong CA, Pringle M, Tattersfield AE. Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: a cross sectional study. BMJ. 1996;313:344–346
  2. Shubin H. Long term (five or more years) administration of corticosteroids in pulmonary diseases. Dis Chest. 1965;48:287–290
  3. Bar-Meir S, Chowers Y, Lavy A, et al. Budesonide versus prednisone in the treatment of active Crohn's disease. The Israeli Budesonide Study Group. Gastroenterology. 1998;115:835–840
  4. Campieri M, Ferguson A, Doe W, Persson T, Nilsson LG. Oral budesonide is as effective as oral prednisolone in active Crohn's disease. The Global Budesonide Study Group. Gut. 1997;41:209–214
  5. Covar RA, Leung DY, McCormick D, Steelman J, Zeitler P, Spahn JD. Risk factors associated with glucocorticoid-induced adverse effects in children with severe asthma. J Allergy Clin Immunol. 2000;106:651–659
  6. Jover JA, Hernandez-Garcia C, Morado IC, Vargas E, Banares A, Fernandez-Gutierrez B. Combined treatment of giant-cell arteritis with methotrexate and prednisone. a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2001;134:106–114
  7. Yanovski JA, Miller KD, Kino T, et al. Endocrine and metabolic evaluation of human immunodeficiency virus-infected patients with evidence of protease inhibitor-associated lipodystrophy. J Clin Endocrinol Metab. 1999;84:1925–1931
  8. Christeff N, Melchior JC, de Truchis P, Perronne C, Nunez EA, Gougeon ML. Lipodystrophy defined by a clinical score in HIV-infected men on highly active antiretroviral therapy: correlation between dyslipidaemia and steroid hormone alterations. Aids. 1999;13:2251–2260
  9. Garg A. Lipodystrophies. Am J Med. 2000;108:143–152
  10. Capeau J, Magre J, Lascols O, et al. Diseases of adipose tissue: genetic and acquired lipodystrophies. Biochem Soc Trans. 2005;33:1073–1077
  11. Fardet L, Cabane J, Kettaneh A, Lebbe C, Flahault A. Corticosteroid-induced lipodystrophy is associated with features of the metabolic syndrome.. Rheumatology (Oxford). 2007;46(7):1102–1106
  12. Fardet L, et al. Corticosteroid-induced clinical adverse events: frequency, risk factors and patient's opinion.. Br J Dermatol. 2007;157(1):42–48
  13. Carr A, Law M. An objective lipodystrophy severity grading scale derived from the lipodystrophy case definition score. J Acquir Immune Defic Syndr. 2003;33:571–576
  14. Carter VM, Hoy JF, Bailey M, Colman PG, Nyulasi I, Mijch AM. The prevalence of lipodystrophy in an ambulant HIV-infected population: it all depends on the definition. HIV Med. 2001;2:174–180
  15. Cohen J. A coefficient of agreement for nominal scales. Educ Psychol Meas. 1960;20:37–46
  16. Grinspoon S, Carr A. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med. 2005;352:48–62
  17. Friis-Moller N, Sabin CA, Weber R, et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med. 2003;349:1993–2003
  18. Ammassari A, Antinori A, Cozzi-Lepri A, et al. Relationship between HAART adherence and adipose tissue alterations. J Acquir Immune Defic Syndr. 2002;31(Suppl 3):S140–S144
  19. Feldt T, Oette M, Kroidl A, et al. Evaluation of safety and efficacy of rosiglitazone in the treatment of hiv-associated lipodystrophy syndrome. Infection. 2006;34:55–61
  20. Tien PC, Benson C, Zolopa AR, Sidney S, Osmond D, Grunfeld C. The study of fat redistribution and metabolic change in HIV infection (FRAM): methods, design, and sample characteristics. Am J Epidemiol. 2006;163:860–869
  21. Nordborg E, Schaufelberger C, Bosaeus I. The effect of glucocorticoids on fat and lean tissue masses in giant cell arteritis. Scand J Rheumatol. 1998;27:106–111

PII: S0953-6205(07)00288-9

doi: 10.1016/j.ejim.2007.09.015

European Journal of Internal Medicine
Volume 19, Issue 5 , Pages 340-344 , July 2008

Article Tools